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CHAPTER ONE 
INTRODUCTION 
Significance 
Bipolar disorder (BD) is a chronic psychiatric illness affecting at least 1% 
of the world population. It is characterized by fluctuations between manic and 
depressed mood states. With an attempted suicide rate of 25-50% (Jamison, 
2000), it is the psychiatric condition most commonly associated with suicide. The 
Global Burden of Disease report documented BD as the sixth greatest cause of 
death or disability globally (Narrow et al., 2002). Approximately 10.3% of all costs 
of global biomedical illnesses are attributed to BD (Andreasen, 2001). Patients 
with BD generally experience high rates of relapse, chronicity, residual 
symptoms, cognitive and functional impairment, as well as psychosocial disability 
leading to damaged relationships and poor job or school performance. A number 
of medications are used to treat BD. However, none of the drugs prescribed to 
treat BD are completely effective, and the development of more effective drugs 
with fewer side-effects is hampered by the lack of knowledge of the therapeutic 
mechanism of action of these drugs and the molecular mechanism underlying 
BD. Therefore, to improve the treatment of BD, it is important to understand the 
therapeutic mechanisms of action of current drugs. 
Treatments for BD 
Medications known as “mood stabilizers” such as lithium, valproate (VPA) 
and lamotrigine are used to treat BD. Atypical antipsychotics have also been 
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used, but most research has focused on lithium and VPA. VPA, the subject of 
this research, is a widely prescribed and established anticonvulsant that was 
approved by the FDA in 1995 as a mood stabilizer to treat BD. It is a simple 
branched-chain fatty acid (2-propylpentanoic acid; 2-propylvaleric acid; di-n-
propylacetic acid) that was found to be an anticonvulsant in 1962 during a screen 
for compounds having anti-seizure activity (as reviewed by Henry, 2003). In spite 
of the wide usage of VPA, many side effects have been identified. The clinical 
side effects of VPA include sedation, gastrointestinal symptoms, tremor and a 
benign increase in hepatic transaminase levels, dyspepsia, weight gain, 
dysphoria, fatigue, dizziness, drowsiness, hair loss, headache and nausea 
(reviewed by Kostrouchova et al., 2007). When used in early pregnancy, VPA 
causes a 3-fold increased risk of congenital anomalies such as neural tube 
defects resulting in spina bifida (Lammer et al., 1987; Koren and Kennedy, 1999; 
Koren et al., 2006).  Another major drawback of VPA is that 20%–40% of patients 
fail to respond satisfactorily. All of these negative effects highlight a great need to 
develop more effective drugs to treat BD. However, the molecular mechanism of 
the therapeutic action of VPA in BD is still unknown. A known target of VPA is 
inositol metabolism (O’Donnell et al., 2000; Vaden et al., 2001; Shaltiel et al., 
2004; Williams et al., 2002). Decreased inositol also results from treatment with 
lithium. The work in this dissertation focuses on the effects of VPA on inositol 
metabolism.  
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Biosynthesis and importance of inositol 
Inositol is an essential molecule ubiquitously found in all biological 
systems. It is a six carbon cyclitol that exists in nine possible isomeric forms 
(myo, L- chiro, D-chiro, scyllo, neo, cis, epi, allo, and muco). Of these, myo-
inositol is physiologically the most common and important isomer (Shi et al., 
2005). Inositol biosynthesis occurs in two steps. In the first step, glucose-6-
phosphate is converted to L-myo-inositol-3-phosphate (MIP) by 1D-myo-inositol-
3 phosphate synthase (MIPS) (Donahue and Henry, 1981). Myo-inositol 
monophosphatase (IMPase) is the second enzyme in the pathway, which 
converts MIP into free myo-inositol (Majumder et al., 1997). In yeast, MIPS is 
encoded by INO1 while INM1 encodes IMPase.  Phosphorylation of the inositol 
ring at one or more positions generates numerous phosphoinositides (PIs) and 
inositol phosphates (IPs) (Fig 1).  
Inositol plays an important role in several cellular processes, including 
protein secretion, growth regulation, signal transduction, transcription regulation, 
and membrane biogenesis (Carman and Henry, 1999; Lohia et al., 1999; Fisher 
et al., 2002). A number of genes show altered expression in response to inositol 
(Nikoloff and Henry, 1991; Paultauf et al., 1992; Lopes et al., 1991; Bailis et al., 
1992). These include genes that affect the processes of lipid biosynthesis, 
protein folding and secretion, vacuole fusion, and others (Jesch et al., 2005).  
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Figure 1: Inositol metabolism: Yeast obtain inositol in three ways: uptake of inositol 
from extracellular fluid by inositol transporters (Itr1p and Itr2p), turnover of inositol 
containing phospholipids, and de novo synthesis. Inositol biosynthesis is a two-step 
pathway: 1D-myo-inositol-3 phosphate synthase (MIPS) converts glucose-6-phosphate 
to inositol-3-phosphate (MIP), which is converted to free myo-inositol by myo-inositol 
monophosphatase (IMPase). Inositol is converted to phosphatidylinositol, then to other 
phosphoinositides (PIs) and inositol phosphates (IPs) in the PI cycle. VPA causes 
inositol depletion by indirect inhibition of MIPS. IP6 inhibits INO1 expression. Current 
Hypothesis: Loss of KCS1 and VIP1 lead to inositol depletion, causing sensitivity to 
VPA. 
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Moreover, perturbation of inositol metabolism is linked to several 
neuropsychiatric disorders such as BD, Parkinson’s disorder, and Alzheimer’s 
disease (Silverstone et al., 2002; LaFerla, 2002).  All of these factors emphasize 
the importance of understanding the effect of VPA on inositol metabolism to 
elucidate its therapeutic mechanism of action. 
Inositol metabolism and VPA 
Evidence shows that VPA interferes with inositol metabolism in yeast 
(O’Donnell et al., 2000; Shaltiel et al., 2004; Williams et al., 2002). VPA 
decreases de novo synthesis of inositol by indirectly inhibiting MIPS activity in 
vivo in yeast (Vaden et al., 2001; Ju et al., 2004). Yeast cells grown in the 
presence of VPA exhibited decreased intracellular inositol and an increase in the 
expression of the structural gene INO1 and the regulatory gene INO2, consistent 
with inositol depletion (Vaden et al., 2001). Some evidence suggests that VPA 
also  interferes with inositol metabolism in mammals. VPA was found to decrease 
activity of human MIPS expressed in yeast cells (Ju et al., 2004) and activity of 
MIPS in crude homogenates of human postmortem prefrontal cortex (Shaltiel et 
al., 2004). Further, VPA reduced brain inositol levels in a magnetic resonance 
spectroscopy study in rats (O'Donnel et al., 2000). Another study showed that 
VPA decreased growth cone collapse and increased growth cone area of rat 
sensory neurons in culture. These effects were eliminated by supplementation 
with inositol (Williams et al., 2002). All of these studies support that VPA depletes 
inositol levels and affects inositol metabolism.  
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IPs are important molecules in inositol metabolism 
IP3, produced by the cleavage of phosphatidylinositol bisphosphate (PIP2) 
by PI-specific phospholipase C (PLC), is further phosphorylated to synthesize 
other IPs (Berridge and Irvine, 1989; Majerus, 1992). These IPs include inositol 
tetrakisphosphate (IP4), inositol pentakisphosphate (IP5), and inositol 
hexakisphosphate (IP6) that are generated through the subsequent action of 
several classes of evolutionarily conserved inositol phosphate kinases (IPKs) 
(Irvine and Schell, 2001; York, 2006; Communi et al., 1994; Shears, 2004). IPs 
have been shown to convey signals for a variety of hormones, growth factors, 
and neurotransmitters (Berridge, 1993; Berridge and Irvine, 1989). Among all 
IPs, IP3 and IP6 are the most highly studied in relation to human disease. 
IP3 is synthesized by the PLC catalyzed hydrolysis of PIP2 (Strahl and 
Thorner, 2007). IP3 is phosphorylated to IP4 and, IP4 is further phosphorylated 
to IP5 by inositol polyphosphate multikinase (IPK2). IP5-kinase (IPK1) 
phosphorylates IP5 to generate IP6 (York et al., 1999), and IP6 is further 
phosphorylated to IP7 and IP8 by Kcs1p and Vip1p, hexakisphosphate kinases 
(IP6Ks) (Luo et al., 2003; Huh et al., 2003). IP3 plays an essential role as a 
second messenger in the IP3/Ca2+ signal transduction pathway that is 
responsible for modulating the activity of numerous cellular processes. IP6 is the 
most abundant inositol phosphate and is found in all mammalian cells. It exhibits 
strong antioxidant properties (Hawkins et al., 1993) and causes inhibition of Fe3+-
catalyzed hydroxyl-radical formation. Other functions of IP6 include inhibition of 
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protein phosphatases (Larsson et al., 1997) and activation of PKC (Efanov et al., 
1997). Anticancer properties have been reported (Fox and Eberl, 2002; Vucenik 
and Shamsuddin, 2003). IP6 is also found in the yeast nucleus and modulates 
mRNA transport out of the nucleus (York et al., 1999). 
 An important effect of IP6 on inositol metabolism is the inhibition of 
nucleosome mobilization of the INO80 complex that positively regulates INO1 
expression (Ford et al., 2007; Shen et al., 2003). However, the effect of IP6 on 
INO1 expression has not been studied. The de novo synthesis of inositol and IPs 
are characterized in the greatest detail in the yeast Saccharomyces cerevisiae, 
and very little is known about inositol metabolism in human cells (reviewed in 
Azab et al., 2008). Therefore, yeast is an ideal model system to carry out 
research to understand the effect of VPA on inositol metabolism and IPs.  
Yeast as a model system 
The baker’s yeast S. cerevisiae has been used as a eukaryotic model 
organism to study the effect of VPA on inositol metabolism (Ju and Greenberg, 
2003; Ju et al., 2004; Vaden et al., 2001). Yeast can be easily used for genetic, 
molecular, and biochemical approaches. The complete sequence of the yeast 
genome and the disruption mutants of all nonessential genes are available. Many 
of the genes that encode components of the PI pathway have been cloned in 
yeast, and regulation of inositol metabolism in yeast is well characterized at a 
molecular level (Greenberg and Lopes, 1996). 
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A high degree of conservation of function between yeast and higher 
eukaryotes indicates that the yeast system can be utilized to understand complex 
eukaryotic cellular processes. Conservation of function with respect to inositol 
metabolism has been demonstrated from yeast to humans, and homologs of the 
yeast genes INO1 and INM1 are present in the human genome. Human MIPS 
and yeast INO1 exhibited 56% amino acid similarity, and human IMPA1 and 
yeast INM1 shared 43% similarity (www.ncbi.nlm.nih.gov). In addition, the 
expression of human MIPS complements the inositol auxotrophy of yeast ino1 
null mutants (Ju et al., 2004). It has also been shown that human MIPS is 
inhibited by VPA (Ju et al., 2004; Shaltiel et al., 2004).   O’ Brien et al., (1990) 
showed that at least 40% of the genes responsible for heritable diseases in 
humans have counterparts in yeast. S. cerevisiae has been successfully used as 
a model for understanding pathogenic mechanisms in Huntington’s disease (HD) 
and Parkinson’s disease (PD) (Willingham et al., 2003). These studies 
demonstrate that yeast is a powerful system that can be utilized to study the 
effect of VPA on IPs and inositol depletion. 
Project outline 
In yeast, VPA causes inositol depletion by indirectly inhibiting MIPS 
encoded by INO1 (Vaden et al., 2001; Ju et al., 2004). Factors that regulate 
INO1 expression in yeast include the transcriptional activators Ino2p/ Ino4p 
(Koipally et al., 1996; Schwank et al., 1995), intracellular inositol levels (Heyken 
et al., 2005) and chromatin remodeling complexes (Shen et al., 2000). The 
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INO80 chromatin remodeling complex positively regulates chromatin remodeling 
at the yeast INO1 promoter (Ford et al., 2007). In yeast, IP6 inhibits the activity of 
the INO80 complex (Shen et al., 2003), suggesting that increased IP6 may lead 
to decreased INO1 expression. KCS1 and VIP1 convert IP6 to IP7 (Luo et al., 
2003; Lin et al., 2009), and loss of KCS1 and VIP1 leads to increased 
intracellular IP6 levels (Dubois et al., 2002; Mulugu et al., 2007). Therefore, I 
hypothesized that perturbation of these pathways may inhibit inositol synthesis 
and increased VPA sensitivity. 
To test the hypothesis, I screened deletion mutants of all genes reported 
to affect inositol metabolism for inositol auxotrophy. kcs1∆ was identified as an 
inositol auxotroph in this screen. I further characterized kcs1∆ with respect to 
inositol metabolism and VPA sensitivity. My results showed that loss of KCS1 
caused VPA sensitivity due to inositol depletion. Because kcs1∆ causes 
increased IP6 levels, I tested other mutants in the IP pathway to determine if 
other mutants that perturb IP6 cause inositol auxotrophy. Of the mutants tested, 
(ipk1∆, ipk2∆, plc1∆ and vip1∆), vip1∆, which increases IP6 exhibited partial 
inositol auxotrophy and VPA sensitivity in contrast to the other mutants, which 
most likely do not affect IP6 levels. In summary, the loss of KCS1 or VIP1 
exacerbates VPA induced inositol depletion. As discussed above, about 50% of 
patients with BD do not respond to VPA (Dilsaver at al., 1993). The current study 
may be relevant to understanding the genetic factors that contribute to 
responsiveness to this drug. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Materials  
All chemicals and reagents used were reagent grade or better. Amino 
acids, myo-inositol and VPA were purchased from Sigma. Vitamin supplements 
were purchased from Difco. Glucose was purchased from Fisher Scientific.  Agar 
was bought from US Biological (Swampscott, MA). Chloroform, methanol, 
ethanol, acid phenol (pH 4.3) and Tris-HCl were bought from Fisher. RNeasy 
Mini Kit was purchased from Qiagen. Transcriptor first strand synthesis kit and 
Dna free kit were purchased from Roche and Ambion. Brilliant SYBR green 
QPCR and 8X optical strip tubes were purchased from Stratagene.   
Growth media  
 Synthetic complete (SC) medium with inositol (I+SC) contained glucose 
(2% w/v), necessary amino acids: adenine, arginine, histidine, methionine, 
tryptophan (20 mg/L), lysine (200 mg/L), uracil (40 mg/L), and leucine (60 mg/L), 
inositol (75µM), ammonium sulphate (0.2% w/v), vitamins (Culbertson and Henry, 
1975) and the components of vitamin-free yeast base: boric acid (200 µg/l), 
calcium chloride (80 µg/l), magnesium sulfate (0.2 g/l), potassium iodide (40 
µg/l), potassium phosphate monobasic (0.4 g/l), sodium molybdate (80 µg/l), and 
zinc sulfate (160 µg/l), plus agar (2% w/v) for solid medium. Synthetic complete 
medium without inositol (I-SC) contained all of the above mentioned ingredients 
except inositol. Synthetic minimal (SM) medium with inositol (I+SM) contained all 
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the necessary ingredients as mentioned for I+SC except adenine, arginine and 
lysine. Synthetic minimal medium without inositol (I-SM) contained all of the 
components in I+SM except inositol. Complex medium (YPD) contained glucose 
(2% w/v), bacto-peptone (2% w/v), agarose (2%w/v), and yeast extract (1% w/v 
Agar (2% w/v) was added to the above mentioned medium for solid medium. 
Cells were grown at 30C unless otherwise indicated. 
Yeast strains 
All the deletion mutants were derived from the deletion collection and were 
isogenic with BY4741 (his3∆1, leu2∆0, met15∆0, ura3∆0) but carried the deletion 
of the specific gene. The list of mutants is given in Table1. 
Growth conditions 
To compare growth patterns, cells were initially grown in liquid YPD 
medium and inoculated to an A550 of 0.01 in SM and SC liquid media with or 
without inositol. To assay inositol-less death, liquid cultures were inoculated from 
cultures grown in the presence of 75 µM inositol for 24 h.  
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Table 1: Deletion mutants screened for inositol auxotrophy (as described in 
the S. cerevisiae Genomic Data base) 
Group Deletion 
mutant 
Protein encoded  
by the gene 
Function of the protein 
(Cited directly from SGD) 
Kinases      kcs1∆ IP5/IP6/IP7 kinase Generates high energy inositol 
pyrophosphates required for  
cellular processes  such as 
vacuolar biogenesis, stress 
response and telomere 
maintenance 
ipk1∆ IP5 kinase Required for synthesis of IP6 
ipk2∆ Inositol polyphosphate 
multikinase 
Sequentially phosphorylates 
IP3 to form IP5; also has 
diphosphoinositol 
polyphosphate synthase 
activity  
vip1∆ 
 
 
 
 
 
 
 
IP6/IP7 kinase Generates  IP7 required for 
phosphate signaling; likely 
involved in cortical actin 
cytoskeleton function 
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 ire1∆ Serine-threonine 
kinase 
Mediates the unfolded protein 
response (UPR) by regulating 
Hac1p synthesis                                                         
 tos3∆ Protein kinase Involved in  phosphorylation 
and activation of Snf1p; 
functionally orthologous to 
LKB1, a mammalian kinase 
associated with Peutz-Jeghers 
cancer-susceptibility syndrome 
ypk1∆ Protein 
serine/threonine/tyrosi
ne kinase 
Involved in control of 
chromosome segregation and 
in regulating entry into meiosis; 
related to mammalian 
glycogen synthase kinases of 
the GSK-3 family 
rck1∆ Protein kinase Involved in the response to 
oxidative stress; identified as 
suppressor of S. pombe cell 
cycle checkpoint mutations 
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lsb6∆ Type II 
phosphatidylinositol 4-
kinase 
Binds Las17p, which is a 
homolog of human  
Wiskott-Aldrich Syndrome 
protein involved in actin patch 
assembly and actin 
polymerization 
 
Phosphatases 
 
ddp1∆ Polyphosphate 
phosphatase 
Hydrolyzes diphosphorylated 
IPs and diadenosine 
polyphosphates; has high 
specificity for diadenosine 
hexa- and pentaphosphates 
ymr1∆ Phosphatidylinositol 3-
phosphate (PI3P) 
phosphatase 
Involved in various protein 
sorting pathways, including 
CVT targeting and endosome 
to vacuole transport 
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dpp1∆ Diacylglycerol 
pyrophosphate 
(DGPP) phosphatase 
Zinc-regulated vacuolar 
membrane-associated lipid 
phosphatase, 
dephosphorylates DGPP to 
phosphatidate (PA) and PI, 
then PA to diacylglycerol; 
involved in lipid signaling and 
cell metabolism 
Vacuolar 
proteins 
vac1∆ 
 
 
 
vac7∆ 
Multivalent adaptor 
protein 
 
 
Integral vacuolar 
membrane protein 
Facilitates vesicle-mediated 
vacuolar protein sorting by 
ensuring high-fidelity vesicle 
docking and fusion 
Involved in vacuole inheritance 
and morphology; activates 
Fab1p kinase activity under 
basal conditions and also after 
hyperosmotic shock 
avt4∆ Vacuolar transporter Exports large neutral amino 
acids from the vacuole 
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 vac14∆ Protein involved in regulated 
 synthesis of PtdIns(3,5)P(2) 
Involved in control of 
trafficking of some 
proteins to the vacuole 
lumen via the MVB, and in 
maintenance of vacuole 
size and acidity; interacts 
with Fig4p; activator of 
Fab1p 
Membrane 
proteins 
csg2∆ Endoplasmic reticulum 
(ER)membrane protein 
Required for 
mannosylation of 
inositolphosphorylceramid
e and for growth at high 
calcium concentrations 
git1∆ Plasma membrane 
permease 
Mediates uptake of 
glycerophosphoinositol 
and 
glycerophosphocholine as 
sources of the nutrients 
inositol and phosphate; 
expression and transport 
rate are regulated by  
phosphate and inositol 
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scs2∆ Integral ER membrane 
protein 
Regulates phospholipid 
metabolism via an 
interaction with the FFAT 
motif of Opi1p, also 
involved in telomeric 
silencing 
 
Transferases cpt1∆ Cholinephosphotransferase Required for 
phosphatidylcholine 
biosynthesis and for 
inositol-dependent 
regulation of EPT1 
transcription 
ipt1∆ Inositolphosphotransferase Involved in synthesis of 
mannose-(inositol-P)2-
ceramide (M(IP)2C), the 
most abundant  
sphingolipid , can mutate  
to resistance to the 
antifungals syringomycin 
E and DmAMP1 and to K. 
lactis zymocin 
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Other 
mutants 
ubx6∆ UBX (ubiquitin regulatory X) 
domain-containing protein 
Interacts with Cdc48p. 
Transcription of UBX6 is 
repressed when cells are 
grown in media containing 
inositol and choline 
mtd1∆ NAD-dependent 5,10-
methylenetetrahydrafolate 
dehydrogenase 
plays a catalytic role in 
oxidation of cytoplasmic 
one-carbon units; 
expression is regulated by 
Bas1p and Bas2p, 
repressed by adenine, and 
may be induced by inositol 
and choline 
opi10∆ Over producer of inositol  Involved in phospholipid 
biosynthesis 
ctr1∆ Choline/ethanolamine 
transporter 
Involved in uptake of 
nitrogen mustard and the 
uptake of glycine betaine 
during hypersaline stress 
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hor7∆ Protein of unknown function Overexpression 
suppresses Ca2+ 
sensitivity of mutants 
lacking inositol 
phosphorylceramide 
mannosyltransferases 
Csg1p and Csh1p; 
transcription is induced 
under hyperosmotic stress 
 tep1∆ Homolog of human tumor 
suppressor gene 
PTEN/MMAC1/TEP1 
Has  lipid phosphatase 
activity and is linked to the 
phosphatidylinositol 
signaling pathway; plays a 
role in normal sporulation 
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The cells were harvested by low speed centrifugation at room temperature, 
washed twice with inositol-free (I-) medium, and reinoculated in I+ or I-media to 
an A550 of approximately 0.1 at time zero. Cells were grown at 30
0C in a rotary 
shaker at 200 rpm. Cell number was calculated by microscopic counting using a 
hemocytometer every two hours. To determine viable cells, serial dilutions were 
plated on YPD and colonies were counted. 
Determining hypersensitivity to VPA 
Cells were grown in liquid SM and SC media with or without inositol to the 
logarithmic phase of growth, at which time different concentrations of VPA were 
added as indicated. A550 was measured every six hours. Cells were also plated 
on liquid SM and SC media with the same concentrations of inositol and VPA as 
used in the liquid cultures. The concentrations of VPA are given in mM. 
Real-time PCR  
Cells were grown to the early stationary phase in the presence or absence 
of VPA (0.6 mM) and were harvested by centrifugation at 3500 rpm for 10 min. 
Total RNA was isolated using the hot phenol extraction method (Elion and 
Warner, 1984).  50 µl of total RNA was passed through a Qiagen gDNA column 
to remove genomic DNA. The sample was then applied to a Qiagen RNeasy spin 
column to enrich for mRNA. cDNAs were synthesized with a Transcriptor First 
Strand cDNA Synthesis Kit (Roche Biochem) according to the manufacturer’s 
protocol. Real-time PCR reactions were performed in a 25 µl volume using 
Brilliant SYBR Green QPCR Master Mix (Stratagene) in 8X optical strip tubes 
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from Stratagene. cDNA for each sample was synthesized in duplicate and each 
cDNA was amplified in triplicate during the RT-PCR reaction. The primers used 
in real-time PCR are listed in Table 2. ACT1 was used as the internal control and 
the RNA level of INO1 was normalized to ACT1 levels in all samples. The 
protocol for the RT-PCR reaction is as follows: denature at 95C for 10 min 
followed by 40 cycles consisting of 60 s at 95C and 60 s at 57C. 
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Table 2: The real-time PCR primers used in this study 
Gene (bp)       Primers      Sequence             Product length  
 
INO1      Forward    5’-AGTCTGTTCTGGCCCAGTTCTTAG-3’                210 
      Reverse    5’-CGGTTATGGCCACCTAACATCAAC-3’ 
 
ACT1      Forward     5’-TCGTGCTGTCTTCCCATCTATCG-3’            218 
      Reverse     5’CGAATTGAGAGTTGCCCCAGAAG-3’ 
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CHAPTER THREE 
RESULTS 
Screen of deletion mutants to identify inositol auxotrophs 
Deletion mutants of genes that affect inositol metabolism (Table 1) were 
screened for inositol auxotrophy. Cells were plated on both YPD and SM plates 
in the presence and absence of inositol and incubated at 30oC. Three potential 
inositol auxotrophs were identified, kcs1∆ (Fig 2-B), vac7∆ (Fig 2-A) and vac14∆ 
(Fig 2-C). Growth of kcs1∆ but not the others was restored by inositol. Therefore, 
kcs1∆ was subjected to further analysis. 
Inositol auxotrophy of kcs1∆ 
 The growth of kcs1∆ was compared to that of the MIPS mutant ino1∆. 
Isogenic WT, kcs1∆ and ino1∆ cells were grown in liquid SM at 30oC in the 
presence and absence of inositol. Both kcs1∆ and ino1∆ exhibited a marked 
decrease in growth compared to the WT in liquid or solid I-SM medium (Fig 3 and 
4). Growth was restored by supplementation of inositol. A more stringent test of 
inositol auxotrophy, inositol-less death, was compared in both ino1∆ and kcs1∆. 
Cells of ino1∆ and kcs1∆ were grown in I+ SM medium and immediately shifted 
to I-SM and I+SM media.  
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Figure 2: kcs1Δ is an inositol auxotroph 
Wild type (WT) and deletion mutant cells were grown to the logarithmic phase 
in liquid YPD. Cell number was determined using a haemocytometer slide, and 104 
cells/ml were spotted on YPD and SM plates in the presence or absence of inositol. 
The plates were incubated at 30oC for 4 days. Arrow (   ) indicates the pattern of 
growth of inositol auxotrophs. 
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Figure 3: Decreased growth of kcs1∆ in the absence of inositol 
WT, kcs1∆ and ino1∆ cells were grown in liquid SM at 30°C, in the 
presence and absence of inositol. Growth was followed by measuring A550. The 
data are representative of two independent experiments in which duplicate 
samples were measured.  
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Figure 4: Decreased growth of kcs1∆ in the absence of inositol 
            WT and kcs1Δ cells were grown in liquid YPD for 24 hrs at 30oC. Cells 
were washed twice and cell number was determined using a haemocytometer 
slide and serially diluted cells were spotted (103 cells/ml, 102cells/ml, 101 cells/ml) 
on SC plates in the presence or absence of inositol (75 µM). The plates were 
incubated at 30oC for 4 days. 
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Viable cells were measured at the times indicated. As seen in Fig. 5, both 
mutants exhibited inositol-less death, although kcs1∆ was slightly less sensitive 
to inositol starvation compared to ino1∆. Taken together, these experiments 
indicate that kcs1∆ is an inositol auxotroph. 
Determination of VPA hypersensitivity of kcs1∆  
Because kcs1∆ is an inositol auxotroph, I hypothesized that the mutant is 
hypersensitive to VPA. To test the VPA sensitivity of kcs1∆, growth of kcs1∆ was 
compared to that of WT in the presence of VPA.  First, cells were plated on I+SM 
in the presence of 0-0.6 mM VPA. Growth was monitored for 3-4 days. As shown 
in Fig 6, the growth of kcs1∆ was more sensitive to VPA than that of WT. To 
further analyze the growth of kcs1∆ in the presence of VPA, cells were grown in 
liquid media to the logarithmic phase of growth, at which time VPA (range 0 - 0.6 
mM) was added. The results obtained in the growth curves showed a gradual 
decrease in growth with increased concentrations of VPA in liquid cultures (Fig 
7). It is clearly seen that the growth of kcs1∆ is more sensitive to VPA than that of 
WT at each concentration of VPA tested.  
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Figure 5: kcs1∆ undergoes inositol-less death  
 Cells of ino1∆ and kcs1∆ were grown overnight in I+ SM media at 30oC. 
Cells were harvested, washed twice with I-SM medium, and immediately shifted 
to I+ or I-media at an A550 of approximately 0.1 at time zero. Cells were harvested 
at the indicated times, serially diluted, plated on YPD plates, and incubated at 
30°C for 9 h. The number of viable cells was determined as described in 
Materials and Methods.  
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Figure 6: kcs1Δ is hypersensitive to VPA  
           WT and kcs1Δ cells were grown in liquid YPD for 24 hrs at 30oC. Cells 
were washed twice, cell number was determined using a haemocytometer slide, 
and serially diluted cells were spotted (105 cells/ml 104 cells/ml 103 cells/ml, 102 
cells/ml and 101 cells/ml) on SM plates in the presence or absence of inositol 
(75µM) and with different concentrations of VPA (mM) added as indicated. The 
plates were incubated at 30oC for 4 days. 
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Figure 7: kcs1Δ is hypersensitive to VPA 
WT and kcs1∆ cells were grown in liquid I+SM at 30°C, in the presence of 
the indicated concentrations of VPA. A550 of the cultures in the stationary phase 
was determined. The data are representative of two independent experiments in 
which duplicate samples were measured. 
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Quantification of INO1 expression in kcs1∆  
As discussed above, INO1 expression is positively regulated by the INO80 
complex, which rearranges the nucleosomes at the INO1 promoter (Ford et al., 
2007). Shen et al (2003) showed that IP6 inhibits INO80-induced nucleosome 
mobilization by inhibiting its ATPase activity. As Kcs1p converts IP6 to IP7 (Luo 
et al., 2003), I hypothesized that loss of KCS1 is expected to lead to increased 
IP6 levels and the subsequent down-regulation of INO1 expression, which could 
explain the inositol auxotrophy of the kcs1∆ deletion mutant. To test this 
possibility, INO1 expression levels were measured by real time-PCR in I+ (75µM) 
medium, as kcs1∆ does not grow in the absence of inositol. As shown in Fig 8, 
INO1 expression in kcs1∆ showed a 5-fold decrease compared to that of WT in 
the stationary phase.  
Interestingly, although VPA caused increased INO1 expression in 
response to inositol depletion in WT (Fig 9-A), consistent with previous studies 
(Vaden et al., 2001), kcs1∆ did not show a significant increase in INO1 
expression in the presence of VPA (Fig 9-B). Therefore, the inability of kcs1∆ to 
increase INO1 expression in response to inositol depletion might explain the 
sensitivity of the mutant to VPA. 
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Figure 8: Loss of KCS1 causes decreased INO1 expression 
WT and kcs1Δ cells were grown in I+SM medium at 30oC to the stationary 
phase. Total RNA was extracted and INO1 mRNA levels were measured by real-
time PCR. INO1 expression levels were normalized to the levels of the internal 
control gene ACT1. The fold change of INO1 expression was calculated with 
respect to WT. Data are representative of two independent experiments in 
duplicate samples. 
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Figure 9: VPA does not increase INO1 expression in kcs1∆   
            WT (A) and kcs1Δ (B) cells were grown in I+SM medium in the presence 
(+) or absence (-) of 0.6 mM VPA at 30oC to the stationary phase. Total RNA was 
extracted and INO1 mRNA levels were measured by real-time PCR. INO1 
expression levels were normalized to the levels of the internal control gene 
ACT1. Data are representative of two independent experiments in duplicate 
samples.                                                            
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Inositol auxotrophy of vip1∆  
The finding that kcs1∆ exhibited inositol auxotrophy suggested that 
perturbation of other IP kinases and /or phosphatases might also lead to inositol 
auxotrophy, particularly those affecting IP6 levels. Therefore, I analyzed ipk1∆, 
ipk2∆, plc1∆ and vip1∆ for this phenotype. 
Of these mutants, vip1∆ is expected to increase IP6 levels. As shown in 
Fig 10-A, fewer colonies were observed in vip1∆ compared to WT on solid 
medium in the absence of inositol. The growth of vip1∆ was analyzed further in 
liquid cultures.  As seen in Fig 12, growth was decreased in I-, and restored upon 
supplementation with inositol. Although the loss of IPK2 did not show a 
significant effect on growth compared to WT in the absence of inositol on solid 
medium (Fig 10-B), ipk2∆ showed slightly less growth than that of WT in I- liquid 
medium (11-C). Here, the growth was restored upon supplementation with 
inositol. However, ipk1∆ and plc1∆ grew similar to WT in both liquid and solid 
medium (Fig 10-A, 11-A & B).  
 VPA sensitivity of vip1Δ 
As IP6K encoded by VIP1 converts IP6 into IP7 (York et al., 2005), the 
loss of VIP1 might increase intracellular IP6 levels, causing inositol depletion and 
VPA sensitivity. Growth of vip1Δ was compared to that of WT in both liquid and 
solid media in the presence of VPA. Cells were plated on I- medium in the 
presence of different concentrations of VPA. Growth was monitored for 3-4 days.  
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Figure 10: vip1∆ shows partial inositol auxotrophy  
Isogenic vip1Δ, ipk1Δ, plc1Δ, ipk2Δ and WT cells were grown in liquid 
YPD for 24 hrs at 30oC. Cells were washed twice, cell number was determined 
using a haemocytometer slide, and serially diluted cells (105 cells/ml, 104 
cells/ml, 103 cells/ml, 102cells/ml, 101 cells/ml ) were spotted on  SM plates in the 
presence or absence of inositol (I) (A). The mutant  ipk2Δ  was spotted  on SC 
plates (B), because SM medium does not support the growth of this mutant. The 
plates were incubated for 4 days. 
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Figure 11: ipk1Δ, ipk2Δ  and plc1Δ and are not inositol auxotrophs  
Cells of ipk1Δ (A) and plc1Δ (B) were grown in liquid SM and ipk2Δ (C) 
was grown in liquid SC in the presence and absence of inositol at 300C. Growth 
was followed by measuring A550. 
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Figure 12: vip1∆ exhibits decreased growth in I-  
 vip1Δ was grown in liquid SM in the presence and absence of inositol at 
300C, and growth was followed by measuring A550. 
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As shown in Fig 13, vip1∆ was hypersensitive to VPA. Growth of mutants, ipk1∆, 
ipk2∆ and plc1∆ was similar to WT.  In order to further analyze the effects of VPA 
on growth, cells were grown to the logarithmic phase, at which time VPA (0-0.6 
mM) was added. A decrease in growth with increased concentrations of VPA was 
seen throughout the growth cycle of vip1∆ (Fig 14), while ipk1∆, ipk2∆, and plc1∆ 
grew similar to WT (Figs 14 and 15). 
The loss of VIP1 causes decreased INO1 expression  
One possible explanation for inositol auxotrophy of vip1∆ is decreased 
expression of INO1 in the mutant.  Consistent with this, INO1 expression in vip1∆ 
was decreased 2-fold compared to that of WT in the stationary phase (Fig 16-A). 
In contrast, plc1∆ and ipk2∆ did not show a significant change in INO1 
expression (Fig 16-A and B). Interestingly, ipk1∆ exhibited a significant increase 
in INO1 expression compared to WT (Fig16-A). As IPK1 converts IP5 to IP6, loss 
of IPK1 may have caused decreased IP6 levels. As Vip1p also converts IP6 to 
IP7 (Lin et al., 2009), it is likely that loss of VIP1 leads to elevated levels of IP6, 
resulting in inhibition of the INO80 complex (Shen et al., 2003), similar to what 
was observed for kcs1∆. 
 
 
           
 
39 
 
 
 
    Figure 13      
         0                             0.05 mM                       0.1mM 
                 
               
               
               
            0.2mM                             0.4mM                           0.6mM  
               
               
               
               
                0                                0.05 mM                           0.1mM 
                   
                   
          0.2mM                            0.4mM                             0.6mM 
                   
                   
vip1∆
∆ 
ipk1∆ 
plc1∆ 
WT 
vip1∆ 
ipk1∆ 
plc1∆ 
WT 
Ipk2∆ 
  Ipk2∆ 
    WT 
    WT 
VPA
VPA
VPA 
VPA 
A 
 
B 
40 
 
 
 
 
Figure 13:  vip1Δ is hypersensitive to VPA 
WT, vip1Δ, ipk1Δ, ipk2∆ and plc1Δ cells were grown in liquid YPD for 24 
hrs at 30oC. Cells were washed twice and cell number was determined using a 
haemocytometer slide. Serially diluted cells (105 cells/ml 104 cells/ml 103 cells/ml, 
102 cells/ml and 101 cells/ml) of WT, vip1Δ, ipk1Δ and plc1∆ were spotted on SM 
plates (A) and ipk2Δ was spotted on SC plates (B) in the absence of inositol and 
with different concentrations of VPA as indicated. The plates were incubated for 
4 days. 
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Figure 14: vip1Δ is sensitive to VPA  
WT, vip1Δ, ipk1Δ and plc1Δ cells were grown to the stationary phase in 
liquid I-SM at 30°C, in the presence of the indicated concentrations of VPA. 
Growth was followed by measuring A550. 
 
 
 
0
0.5
1
1.5
2
2.5
1 2 3 4 5 6 7 8 9
Series1
Series2
Series3
Series4
WT 
 
0         0.05        0.1        0.2         0.4        0.6         1.00       2.00       5.00 
plc1∆ 
v p1∆ 
 
ipk1∆ 
 A
 5
5
0
  
 
VPA (mM) 
 
42 
 
 
 
 
 
 
 
 
 
Figure 15: ipk2Δ is not sensitive to VPA   
WT and ipk2Δ cells were grown to the stationary phase in liquid I-SC at 
30°C, in the presence of the indicated concentrations of VPA. Growth was 
followed by measuring A550.  
 
 
 
0
0.5
1
1.5
2
2.5
1 2 3 4 5 6 7 8 9
Series1
Series2 A
 5
5
0
  
 
0         0.05        0.1        0.2         0.4        0.6         1.00       2.00       5.00 
VPA (mM) 
 
Ipk2∆ 
WT 
43 
 
 
 
              
 
Figure 16: Loss of VIP1 causes decreased INO1 expression 
 vip1Δ, ipk1Δ, plc1Δ, and WT  (A) were grown in I-SM medium and ipk21Δ  
(B) was grown in I-SC medium at 30oC to the stationary phase. Total RNA was 
extracted and INO1 mRNA levels were measured by real-time PCR. INO1 
expression levels were normalized to the levels of the internal control gene 
ACT1. The fold change of INO1 expression was calculated with respect to WT. 
Data are representative of two independent experiments in duplicate samples. 
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CHAPTER FOUR 
DISCUSSION 
The major finding in this study is that deletion mutants of KCS1 and VIPI 
genes that affect IP6 synthesis confer inositol auxotrophy and sensitivity to VPA. 
KCS1 and VIPI are inositol kinases in the PI cycle. Kcs1p phosphorylates IP5 to 
IP6, IP6 to IP7, and IP7 to IP8 (Luo et al., 2003; Saiardi et al., 2000). Vip1p is 
also an IP6K, which phosphorylates the 4/6 positions of IP6 and IP7 while Kcs1p 
phosphorylates the 5 position in IP4, IP6 and IP7. (Lin et al., 2009). Loss of 
IP6Ks results in pleiotropic cellular defects, including aberrant DNA 
recombination, abnormal vacuolar morphology, altered gene expression, 
increased chemotaxis, osmotic stress, altered protein phosphorylation, and 
decreased telomere length (York 2006, Bennett et al., 2006). The results shown 
here indicate that KCS1 and VIPI are necessary for inositol biosynthesis, and this 
may in part explain some of the cellular phenotypes observed in IP6K mutants. 
The present study also demonstrates that both kcs1∆ and vip1∆ mutants 
are hypersensitive to VPA. As discussed above, our lab has shown that VPA 
causes inositol depletion, and that inositol supplementation rescues sensitivity to 
VPA. Therefore, the most likely explanation for VPA sensitivity of these mutants 
is that loss of KCS1 or VIP1 results in a decrease in inositol levels that 
exacerbates the VPA induced inositol depletion. A key finding in this research is 
that kcs1∆ and vip1∆ mutants exhibit decreased INO1 expression, suggesting 
that the substrates and/or the products of KCS1 and VIP1 regulate INO1 
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expression. As described earlier, increased IP6 due to the loss of KCS1 and 
VIP1 might inhibit INO1 expression by affecting the chromatin remodeling 
complex INO80. 
In order to determine the relevance of this study to BD, it is important to 
consider the current knowledge concerning the human homologs of KCS1, VIP1 
and the INO80 complex, and how these factors affect the regulation of INO1 
expression. The human homolog of yeast KCS1 is h-IP6K (Saiardi et al., 1999). 
Two human VIP1-like IP6 kinases have also been cloned and characterized 
(Fridy et al., 2007). Both of these IP6 kinases convert IP6 to IP7 (Saiardi et al., 
1999; Fridy et al., 2007). The route by which animals synthesize IP6 is similar to 
that used by yeast. In contrast to slime moulds and plants, which synthesize IP6 
by stepwise phosphorylation directly from inositol, animals incorporate the first 
three phosphates while the inositol is in its lipid form. That is, I(1,4,5)P3  formed 
by PLC catalyzed cleavage of PI-(4,5)P2 is sequentially phosphorylated to IP6. 
Therefore, human homologs of KCS1 and VIP1 may play similar roles in inositol 
metabolism as the counterparts yeast. 
 The human INO80 (hINO80) chromatin remodeling contains eight 
subunits orthologous to yeast, including Ino80 ATPase (Jin et al., 2005), as well 
as additional metazoan-specific subunits (Kobor et al., 2004; Kusch 2004). The 
cloning, expression, and functional activity of the hINO80 gene revealed its DNA 
dependent ATPase and DNA binding activity (Bakshi et al., 2006). There are no 
studies regarding the role of the hINO80 complex or IP6 in h-INO1 expression. 
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However, if the roles of IP6 and hINO80 in inositol biosynthesis are conserved 
from yeast to humans, we can speculate that mutations in human homologs of  
KCS1 and VIP1 may affect patients’ responsiveness and resistance to VPA. 
An important unanswered question is if decreased INO1 expression in the 
kcs1∆ and vip1∆ mutants leads to decreased intracellular inositol. It would also 
be interesting to determine if over expression of KCS1 and VIP1 affects 
sensitivity to VPA. Finally, an analysis of IP6 levels in all of the mutants of IP 
synthesis would help to elucidate the mechanism underlying altered INO1 
expression in mutants of IP synthesis. 
In summary, my data show that KCS1 and VIP1 are required for optimal 
synthesis of inositol, and that loss of these genes leads to sensitivity to VPA. This 
finding may have implications for responsiveness to VPA. About half of BD 
patients do not respond to VPA for reasons that have not been identified 
(Dilsaver at al., 1993). Mutations in genes that affect inositol metabolism, such as 
KCS1 and VIP1, may affect patients’ responsiveness to VPA. Understanding the 
genetic factors that affect the responsiveness to VPA would contribute greatly to 
improving treatment efficacy for BD.  
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ABSTRACT 
IDENTIFICATION  OF  DELETION  MUTANTS  OF  INOSITOL  KINASES  AND 
PHOSPHATASES  HYPERSENSITIVE  TO  VALPROATE 
by 
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MAY  2010 
Advisor: Dr. Miriam Greenberg 
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Degree: Master of Science  
Bipolar disorder (BD) is a chronic psychiatric illness affecting at least 1% 
of the world population. BD is ranked as the sixth greatest cause of death or 
disability globally. The cause of BD is unknown. Although the anticonvulsant 
valproate (VPA) is widely used as a mood stabilizer to treat BD, VPA is not 
completely effective and causes numerous side effects. Hence, it is important to 
develop more effective drugs with fewer side effects to treat BD. However, drug 
development is hampered by the lack of knowledge of the therapeutic 
mechanisms of action of current drugs used to treat BD. 
VPA depletes inositol in yeast and mammals. The current study was 
undertaken to determine whether genes affecting inositol synthesis lead to VPA 
sensitivity.1D-myo-inositol-3 phosphate synthase (MIPS) encoded by INO1 
converts glucose-6-phosphate to L-myo-inositol-3-phosphate (MIP) in the de 
novo synthesis of inositol. The activation of INO1 expression is positively 
60 
 
 
 
regulated by the INO80 complex, which is inhibited by   IP6. KCS1 and VIP1 are 
inositol hexakisphosphate kinases that convert IP6 to IP7. 
 I found that kcs1∆ is an inositol auxotroph and vip1∆ is a partial inositol 
auxotroph. Both kcs1∆ and vip1∆ mutants exhibited hypersensitivity to VPA. I 
also found that loss of KCS1 and VIP1 cause decreased INO1 expression. The 
results of the study suggested that perturbation of IP synthesis exacerbates VPA 
induced inositol depletion. These findings have implications for understanding the 
mechanisms underlying responsiveness or resistance to VPA in bipolar patients. 
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